UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

Recruiting · NCT06726720 · Observational (researchers observe without assigning treatment) · Lead sponsor: AstraZeneca

View the official record on ClinicalTrials.gov →

What this trial is about

This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries. Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria. Treatment plan and decision are made independently by each treating physician prior to inclusion in this study.

Who can take part

Age range

18 Years and older

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not specified

Study type

Observational (researchers observe without assigning treatment)

Inclusion criteria

Adult patients (≥ 18 years old)
Patients with histologically or cytologically proven NSCLC
Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks.
Informed patients who consent to participate in the study as per local regulations.

Exclusion criteria

Patients participating in an interventional clinical trial for NSCLC\*
\* with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment
Patients already enrolled in another module of the cohort in UMBREALUNG
Patients under safeguard of justice, curatorship or guardianship

Where it is running

60 locations listed.

Research Site - Aix-en-Provence, France
Research Site - Angers, France
Research Site - Aurillac, France
Research Site - Auxerre, France
Research Site - Avignon, France
Research Site - Berlin, Germany
Research Site - Bezannes, France
Research Site - Blois, France
Research Site - Bordeaux, France
Research Site - Bourg-en-Bresse, France
Research Site - Béziers, France
Research Site - Caen, France
Research Site - Carcassonne, France
Research Site - Chalon Sur Sa Ne, France
Research Site - Chambéry, France
Research Site - Châteauroux, France
Research Site - Créteil, France
Research Site - Dieppe, France
Research Site - Dinan, France
Research Site - Dresden, Germany
Research Site - Dreux, France
Research Site - Epagny METZ Tessy, France
Research Site - Fort de France Cedex, France
Research Site - Frankfurt am Main, Germany
Research Site - Frankfurt am Main, Germany
Research Site - Halle, Germany
Research Site - Hamburg, Germany
Research Site - Hanover, Germany
Research Site - Hanover, Germany
Research Site - Hanover, Germany
Research Site - Heidelberg, Germany
Research Site - Kassel, Germany
Research Site - L Rrach, Germany
Research Site - Landshut, Germany
Research Site - Le Coudray, France
Research Site - Limoges, France
Research Site - Lyon, France
Research Site - M Nnerstadt, Germany
Research Site - Magdeburg, Germany
Research Site - Marseille, France
Research Site - Marseille, France
Research Site - Marseille, France
Research Site - Meaux, France
Research Site - Metz, France
Research Site - Metz, France
Research Site - Mulhouse, France
Research Site - N MES, France
Research Site - Nancy, France
Research Site - Nantes, France
Research Site - Neuilly-sur-Seine, France
Research Site - Neuss, Germany
Research Site - Nice, France
Research Site - Perpignan, France
Research Site - Reims, France
Research Site - Rouen, France
Research Site - Saint-Brieuc, France
Research Site - Saint-Etienne, France
Research Site - Saint-Herblain, France
Research Site - Saint-Priest-en-Jarez, France
Research Site - Schorndorf, Germany

Showing 60 of 70 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →